Outcomes in patients with B-NHL after CAR19/22 T-cell cocktail therapy. (A) The duration of response in the 26 patients with B-NHL who achieved an overall response, including patients with CR and those with a PR. PFS (B) and OS (C) in the entire B-NHL cohort. The median PFS was 9.9 months (95% CI, 3.3-NR), and the median OS was 18.0 months (95% CI, 6.1-NR). PFS (D) and OS (E), according to the response status at month 3 after CAR19/22 T-cell cocktail therapy. Of the patients who achieved an overall response at month 3 (responders), the median PFS and median OS were NR. Of the patients who did not have a response at month 3 (nonresponders), the median PFS was 2.4 months (95% CI, 1.0-2.7), and the median OS was 5.1 months (95% CI, 1.9-6.1).